Old Mission Capital’s Aldeyra Therapeutics ALDX Stock Holding History

Old Mission Capital’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-21,650	Closed	-$148K	–	717
2020 Q4	$148K	Buy	+21,650	New	+$152K	0.01%	498
2020 Q3	–	Sell	-68,900	Closed	-$287K	–	426
2020 Q2	$287K	Buy	+68,900	New	+$252K	0.02%	334

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Old Mission Capital's ALDX Position: Q1 2021 in Review

Old Mission Capital sold out of Aldeyra Therapeutics (ALDX) in Q1 2021, closing a stake of 21,650 shares — an estimated $148K sold.

Old Mission Capital first reported a position in ALDX in Q2 2020 and held it in 2 quarters. The position peaked at $287K in Q2 2020. 108 funds tracked by Wall St. Rank hold ALDX as of Q1 2021.

Old Mission Capital reported no remaining Aldeyra Therapeutics position as of Q1 2021 after selling out during the quarter.
Old Mission Capital sold 21,650 Aldeyra Therapeutics shares in Q1 2021, an estimated $148K.
Old Mission Capital first reported a position in Aldeyra Therapeutics in Q2 2020 and held it in 2 quarters.
Old Mission Capital's Aldeyra Therapeutics position peaked at $287K in Q2 2020.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2021.

Based on Old Mission Capital's 13F filing for Q1 2021, filed 14 May 2021.